Techniques of extracorporeal cytokine removal: A systematic review of human studies

Renal Failure

Volumn 35, Issue 8, 2013, Pages 1061-1070

  Atan, Rafidah ^a   Crosbie, David C A ^b   Bellomo, Rinaldo ^c,d  

^a MONASH UNIVERSITY MALAYSIA   (Malaysia)

^b NORTHERN HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d Department of Intensive Care ^*  (Australia)

Author keywords

Cytokines; Dialysis; Hemofiltration; Interleukins; Plasmafiltration

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD FILTRATION; CARDIOPULMONARY BYPASS; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DIAFILTRATION; EXTRACORPOREAL BLOOD PURIFICATION; HEMOFILTRATION; HUMAN; LIVER SUPPORT; MODIFIED ULTRAFILTRATION; PLASMAPHERESIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; WARMING;

BLOOD COMPONENT REMOVAL; CYTOKINES; HEMOFILTRATION; HUMANS;

EID: 84881598949     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.815089     Document Type: Article

References (56)

1. Beale R, Reinhart K, Brunkhorst F, Dobb G, Levy M, Martin G. Promoting global research excellence in severe sepsis (PROGRESS): lessons from an International Sepsis Registry. Infection. 2009; 37: 222-232.
2. Cabre L, Mancebo J, Solsona JF, et al. Multicenter study of the multiple organ dysfunction syndrome in intensive care units: the usefulness of Sequential Organ Failure Assessment scores in decision making. Intensive Care Med. 2005; 31: 927-933.
3. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med. 1996; 24: 1125-1128.
4. Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a primer. Crit Care Med. 2009; 37: 291-304.
5. Schefold JC, Hasper D, Jörres A. Organ crosstalk in critically ill patients: hemofiltration and immunomodulation in sepsis. Blood Purif. 2009; 28: 116-123.
6. Ronco C, Tetta C, Mariano F, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artificial Organs. 2003; 27: 792-801.
7. Fisher Jr CJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. J Am Med Assoc. 1994; 271: 1836-1843.
8. Opal SM, Fisher Jr CJ, Dhainaut JF, et al. Confirmatory interleukin- 1 receptor antagonist trial in severe sepsis: a phase III, randomized, doubleblind, placebo-controlled, multicenter trial. The Interleukin- 1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997; 25: 1115-1124.
9. Kellum JA, Bellomo R, Mehta R, Ronco C. Blood purification in non-renal critical illness. Blood Purif. 2003; 21: 6-13.
10. Venkataraman R, Subramanian S, Kellum JA. Clinical review: extracorporeal blood purification in severe sepsis. Crit Care. 2003; 7: 139-145.
11. Ronco C, Inguaggiato P, D'Intini V, et al. The role of extracorporeal therapies in sepsis. J Nephrol. 2003; 16(Suppl 7): S34-S41.
12. Stadlbauer V, Krisper P, Aigner R, et al. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care. 2006; 10: R169-R175.
13. Morgera S, Haase M, Kuss T, et al. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med. 2006; 34: 2099-2104.
14. Peng Y, Yuan Z, Li H. Removal of inflammatory cytokines and endotoxin by veno-venous continuous renal replacement therapy for burned patients with sepsis. Burns. 2005; 31: 623-628.
15. Morgera S, Slowinski T, Melzer C, et al. Renal replacement therapy with high-cutoff hemofilters: impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis. 2004; 43: 444-453.
16. Morgera S, Rocktäschel J, Haase M, et al. Intermittent high permeability hemofiltration in septic patients with acute renal failure. Intensive Care Med. 2003; 29: 1989-1995.
17. Dahaba AA, Elawady GA, Rehak PH, List WF. Procalcitonin and proinflammatory cytokine clearance during continuous venovenous hemofiltration in septic patients. Anaesth Intensive Care. 2002; 30: 269-274.
18. Kellum JA, Johnson JP, Kramer D, Palevsky P, Brady JJ, Pinsky MR. Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Crit Care Med. 1998; 26: 1995-2000.
19. Sanchez-Izquierdo JA, Perez Vela JL, Lozano Quintana MJ, Alted Lopez E, Ortuno de Solo B, Ambros Checa A. Cytokines clearance during venovenous hemofiltration in the trauma patient. Am J Kidney Dis. 1997; 30: 483-488.
20. Sander A, Armbruster W, Sander B, Daul AE, Lange R, Peters J. Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF alpha plasma concentrations. Intensive Care Med. 1997; 23: 878-884.
21. van Bommel EF, Hesse CJ, Jutte NH, Zietse R, Bruining HA, Weimar W. Impact of continuous hemofiltration on cytokines and cytokine inhibitors in oliguric patients suffering from systemic inflammatory response syndrome. Ren Fail. 1997; 19: 443-454.
22. Heering P, Morgera S, Schmitz FJ, et al. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intensive Care Med. 1997; 23: 288-296.
23. Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D. Effect of hemofiltration on hemodynamics and systemic concentrations of anaphylatoxins and cytokines in human sepsis. Intensive Care Med. 1996; 22: 1360-1367.
24. Bellomo R, Tipping P, Boyce N. Interleukin-6 and interleukin-8 extraction during continuous venovenous hemodiafiltration in septic acute renal failure. Ren Fail. 1995; 17: 457-466.
25. van Bommel EF, Hesse CJ, Jutte NH, Zietse R, Bruining HA, Weimar W. Cytokine kinetics (TNF-alpha, IL-1 beta, IL-6) during continuous hemofiltration: a laboratory and clinical study. Contrib Nephrol. 1995; 116: 62-75.
26. Bellomo R, Tipping P, Boyce N. Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med. 1993; 21: 522-526.
27. Byrick RJ, Goldstein MB, Wong PY. Increased plasma tumor necrosis factor concentration in severe rhabdomyolysis is not reduced by continuous arteriovenous hemodialysis. Crit Care Med. 1992; 20: 1483-1486.
28. Antunes N, Dragosavc D, Petrucci Junior O, et al. The use of ultrafiltration for inflammatory mediators removal during cardiopulmonary bypass in coronary artery bypass graf surgery. Rev Bras Cir Cardiovasc. 2008; 23: 175-182.
29. Brancaccio G, Villa E, Girolami E, et al. Inflammatory cytokines in pediatric cardiac surgery and variable effect of the hemofiltration process. Perfusion. 2005; 20: 263-268.
30. Berdat PA, Eichenberger E, Ebell J, et al. Elimination of proinflammatory cytokines in pediatric cardiac surgery: analysis of ultrafiltration method and filter type. J Thorac Cardiovasc Surg. 2004; 127: 1688-1696.
31. Dittrich S, Aktuerk D, Seitz S, et al. Effects of ultrafiltration and peritoneal dialysis on proinflammatory cytokines during cardiopulmonary bypass surgery in newborns and infants. Eur J Cardiothorac Surg. 2004; 25: 935-940.
32. Ronco C, Brendolan A, Lonnemann G, et al. A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med. 2002; 30: 1250-1255.
33. Kiziltepe U, Uysalel A, Corapcioglu T, Dalva K, Akan H, Akalin H. Effects of combined conventional and modified ultrafiltration in adult patients. Ann Thorac Surg. 2001; 71: 684-693.
34. Bogǎ M, Islamoǧlu F, Badak I, et al. The effects of modified hemofiltration on inflammatory mediators and cardiac performance in coronary artery bypass grafting. Perfusion. 2000; 15: 143-150.
35. Hoffmann JN, Werdan K, Hartl WH, Jochum M, Faist E, Inthorn D. Hemofiltrate from patients with severe sepsis and depressed left ventricular contractility contains cardiotoxic compounds. Shock. 1999; 12: 174-180.
36. Toft P, Kehler D, Brandslund I I, Tønnsen E. The immunological effects of continuous veno-venous hemodiafiltration in critically ill patients. Crit Care. 1999; 3: 159-165.
37. Watanabe T, Sakai Y, Mayumi T, et al. Effect of ultrafiltration during cardiopulmonary bypass for pediatric cardiac surgery. Artif Organs. 1998; 22: 1052-1055.
38. Wang W, Huang HM, Zhu DM, Chen H, Su ZK, Ding WX. Modified ultrafiltration in paediatric cardiopulmonary bypass. Perfusion. 1998; 13: 304-310.
39. Hoffmann JN, Faist E, Deppisch R, Hartl WH, Inthorn D. Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Contrib Nephrol. 1995; 116: 76-79.
40. Xie H, Ji D, Gong D, et al. Continuous veno venous hemofiltration in treatment of acute necrotizing pancreatitis. Chin Med J (Engl). 2003; 116: 549-553.
41. Mariano F, Tetta C, Guida G, Triolo G, Camussi G. Hemofiltration reduces the serum priming activity on neutrophil chemiluminescence in septic patients. Kidney Int. 2001; 60: 1598-1605.
42. Reeves JH, Butt WW, Shann F, et al. Continuous plasma filtration in sepsis syndrome. Plasma filtration in Sepsis Study Group. Crit Care Med. 1999; 27: 2096-2104.
43. De Vriese AS, Colardyn FA, Philippé JJ, Vanholder RC, De Sutter JH, Lameire NH. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol. 1999; 10: 846-853.
44. Clar A, Bowers MC, Larson DF. Derivation of sieving coefficients to determine the efficacy of the hemoconcentrator in removal of four inflammatory mediators produced during cardiopulmonary bypass. ASAIO J. 1997; 43: 163-170.
45. Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D. Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Kidney Int. 1995; 48: 1563-1570.
46. Tsuchida K, Takemoto Y, Sugimura K, Yoshimura R, Nakatani T. Direct hemoperfusion by using Lixelle column for the treatment of systemic inflammatory response syndrome. Int J Mol Med. 2002; 10: 485-488.
47. Yonekawa C, Nakae H, Tajimi K, Asanuma Y. Effectiveness of combining plasma exchange and continuous hemodiafiltration in patients with postoperative liver failure. Artif Organs. 2005; 29: 324-328.
48. Tallman RD, Dumond M, Brown D. Inflammatory mediator removal by zero-balance ultrafiltration during cardiopulmonary bypass. Perfusion. 2002; 17: 111-115.
49. Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P. High-volume hemofiltration in human septic shock. Intensive Care Med. 2001; 27: 978-986.
50. Nishida O, Nakamura T, Kuriyama N, et al. Sustained highefficiency daily diafiltration using a mediator-adsorbing membrane (SHEDD-fA) in the treatment of patients with severe sepsis. Contrib Nephrol. 2011; 173: 172-181.
51. Schilder L, Nurmohamed SA, ter Wee PM, et al. Effect of anticoagulation regimens on handling of interleukin-6 and -8 during continuous venovenous hemofiltration in critically ill patients with acute kidney injury. Cytokine. 2012; 60: 601-607.
52. Oishi K, Mimura-Kimura Y, Miyasho T, et al. Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis. Cytokine. 2013; 61: 84-89.
53. Atan R, Crosbie D, Bellomo R. Techniques of extracorporeal cytokine removal: a systematic review of the literature. Blood Purif. 2012; 33: 88-100.
54. Atan R, Crosbie D, Bellomo R. Techniques of extracorporeal cytokine removal: a systematic review of the literature on animal experimental studies. Int J Artif Organs. 2013; 36: 149-158.
55. Brain M, Anderson M, Parkes S, Fowler P. Magnesium flux during continuous venous hemodiafiltration with heparin and citrate anticoagulation. Crit Care Resusc. 2012; 14: 274-282.
56. Brain M, Parkes S, Fowler P, Robertson I, Brown A. Calcium flux in continuous venovneous hemodiafiltration with heparin and citrate anticoagulation. Crit Care Resusc. 2011; 13: 72-81.